New combo therapy for tough prostate cancer shows promise in early trial

NCT ID NCT03737370

Completed Disease control Sponsor: Tufts Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a combination of two drugs—docetaxel (a chemotherapy) and radium 223 (a radioactive drug)—in 43 men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The main goal was to find the safest dose and watch for side effects. Researchers also tracked how long the cancer stayed under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Docetaxel (chemotherapy) and Radium 223 (radioactive drug)
What this could lead to: If successful, this could lead to a safer and more effective combination treatment for men with advanced prostate cancer that has spread to the bones.
What could go wrong: This is an early phase 1 trial focused on safety and dosing, not on proving the treatment works. The combination may cause serious side effects like low blood cell counts or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATE RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Henry Ford Health System

Detroit, Michigan, 48202, United States
Lahey Hospital & Medical Center

Boston, Massachusetts, 01805, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Tufts Medical Center

Boston, Massachusetts, 02111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.